2016 ACR/ARHP Annual Meeting

November 11-16, 2016. Washington, DC.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 804

Combined-Phenotype Meta-GWAS in Systemic Sclerosis and Rheumatoid Arthritis Identifies IRF4 As a New Common Susceptibility Locus
Abstract Number: 1107

Combining Scaffold-Free Cartilage Transplants to Controlled Gene Expression for Therapeutic Application in Rheumatic Disorders
Abstract Number: 450

Coming Full Circle with the Omeract RA Flare Questionnaire (RA-FQ): Further Evaluation of the Properties, Meaningfulness, and Utility through Rasch Analysis and Feedback from RA Patients
Abstract Number: 187

Commensal Microbiota Tune Systemic Toll-like Receptor-Mediated Inflammatory Responses
Abstract Number: 1834

Commensal Ro60 Autoantigen Ortholog Cross-Reactivity in Human Lupus and Gnotobiotic Models
Abstract Number: 2565

Common Biomarker Elevations in Idiopathic Pulmonary Fibrosis and Rheumatoid Arthritis-Associated Interstitial Lung Disease
Abstract Number: 43

Comorbid Development of Fibromyalgia and Posttraumatic Stress Disorder after Exposure to a Combat Environment
Abstract Number: 2176

Comorbidities and DMARD, NSAID and Steroid Use in a Real Life Cohort of 8,981 Patients with Psoriatic Arthritis
Abstract Number: 397

Comorbidities Associated with Pediatric Psoriatic Arthritis
Abstract Number: 1550

Comorbidities of Rheumatoid Arthritis: Results from the Korean National Health and Nutrition Examination Survey
Abstract Number: 2776

Comparability of Patients Classified As Non-Radiographic Axial Spondyloarthritis By the Imaging Vs Clinical Arms of the ASAS Criteria
Abstract Number: 407

Comparability of Proxy, Adolescent and Adult Measures of Functional Ability in Adolescents with JIA
Abstract Number: 2596

Comparable Safety and Immunogenicity and Sustained Efficacy after Transition to SB2 (An Infliximab Biosimilar) Vs Ongoing Reference Infliximab (Remicade®) in Patients with Rheumatoid Arthritis: Results of Phase III Transition Study
Abstract Number: 149

Comparation of Ultrasonic Imaging of Enthesopathy in the Lower Extremity in Patients with Psoriatic Arthritis, Psoriasis and Other Inflammatory Arthritis
Abstract Number: 2809

Comparative Analysis of Anti-Nuclear Antibody Testing Using Blinded Replicate Samples Reveals Variability Between Commercial Testing Laboratories

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].